0001185185-18-000849.txt : 20180511 0001185185-18-000849.hdr.sgml : 20180511 20180511135042 ACCESSION NUMBER: 0001185185-18-000849 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20180508 ITEM INFORMATION: Bankruptcy or Receivership ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20180511 DATE AS OF CHANGE: 20180511 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MEDIZONE INTERNATIONAL INC CENTRAL INDEX KEY: 0000753772 STANDARD INDUSTRIAL CLASSIFICATION: WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122] IRS NUMBER: 870412648 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 002-93277-D FILM NUMBER: 18826222 BUSINESS ADDRESS: STREET 1: 350 EAST MICHIGAN AVENUE STREET 2: SUITE 500 CITY: KALAMAZOO STATE: MI ZIP: 49007 BUSINESS PHONE: (269) 202-5020 MAIL ADDRESS: STREET 1: 350 EAST MICHIGAN AVENUE STREET 2: SUITE 500 CITY: KALAMAZOO STATE: MI ZIP: 49007 FORMER COMPANY: FORMER CONFORMED NAME: MADISON FUNDING INC DATE OF NAME CHANGE: 19860413 8-K 1 medizone8k051018.htm 8-K


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 

 
FORM 8-K
 

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of Report (Date of earliest event reported): May 8, 2018
 
MEDIZONE INTERNATIONAL, INC.
(Exact name of registrant as specified in its charter)
 
Nevada
(State or other jurisdiction of incorporation)
2-93277-D
(Commission File Number)
87-0412648
(I.R.S. Employer Identification No.)
 
350 East Michigan Avenue, Suite 500, Kalamazoo, MI 49007
(Address of principal executive offices, Zip Code)
 
(269) 202-5020
(Registrant’s telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
 
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 

Item 1.03.  Bankruptcy or Receivership.

On May 8, 2018, Medizone International, Inc., a Nevada corporation (the “Company”), commenced a voluntary bankruptcy proceeding under Chapter 7 of the United States Bankruptcy Code (the “Code”) in the United States Bankruptcy Court for the District of Nevada (the “Bankruptcy Case”). The Bankruptcy Case is styled “In re Medizone International Inc., Debtor, No. 18-12662”. As a result of filing of the Bankruptcy Case, Lenard F. Schwartzer, Esq., Schwartzer & McPherson Law Firm, 2850 South Jones Boulevard, Suite 1, Las Vegas, Nevada 89146 (702-228-7590) has been appointed as Chapter 7 trustee by the Bankruptcy Court and has assumed control of the Company. The assets of the Company will be liquidated in accordance with the Code.

Item 8.01  Other Events.

The Company has determined that, as a result of its financial condition, it will not file its Quarterly Report on Form 10-Q for the quarter ended on March 31, 2018, or any subsequent report pursuant to the Securities and Exchange Act of 1934, as amended. The Company does not have sufficient funds to pay for the preparation, review or filing of such reports.

Item 9.01.  Financial Statements and Exhibits.

  (d)       Exhibits

99.1
 

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: May 11, 2018
 
 
MEDIZONE INTERNATIONAL, INC.
 
 
 
By: /s/ David A. Dodd                                                      
Chief Executive Officer
   
 
 
EX-99.1 2 ex99-1.htm EX-99.1
 
Exhibit 99.1

Medizone International Announces Filing of Voluntary Chapter 7 Bankruptcy Proceeding
 
Kalamazoo, Michigan, May 8, 2018.  Medizone International, Inc. (OTCQB:MZEI), or Medizone, manufacturer of the AsepticSure® system, announced that it today has filed a voluntary petition in bankruptcy seeking liquidation of the Company pursuant to Chapter 7 of the United States Bankruptcy Code. The petition was filed in the United States Bankruptcy Court for the District of Nevada. It has been assigned case number 18-12662. Medizone is represented in the bankruptcy filing by Mathew C. Zirzow, Esq., of Larson Zirzow & Kaplan, LLC, Las Vegas, Nevada.
 
About Medizone International, Inc.
 
Medizone International, Inc. is focused on commercializing the AsepticSure® System, a superior disinfectant technology compared to conventional systems or practices.  The company developed the AsepticSure® System to combine oxidative compounds (O3 and H2O2) to produce a unique mixture of free radicals (H2O3 known as trioxidane) with much higher oxidative potential than ozone or hydrogen peroxide alone.  After securing broad IP protection for the use of trioxidane for both healthcare and non-healthcare facility disinfecting systems and bioterrorism applications, Medizone released its AsepticSure® System for use in Canada, and several other global markets.
 
For press information on Medizone International, please contact:
For more information, visit:
www.medizoneint.com
Email: operations@medizoneint.com